Trial reportJournal of gynecologic oncology2022
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Trial report in Journal of gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04734665 (A Single-arm Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration.Journal of gynecologic oncology · 2026Article
- PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience.Journal of ovarian research · 2025Article
- Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis.Journal of gynecologic oncology · 2025Article
- Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab-20 Years of Therapeutic Success and Controversy.Cancers · 2025Review
- Asian Society of Gynecologic Oncology (ASGO) 2024 Annual Meeting in Bali, Indonesia.Journal of gynecologic oncology · 2025Article
- Analysis of m7G-related signatures in the tumor immune microenvironment and identification of clinical prognostic regulators in ovarian cancer.Frontiers in immunology · 2025Article
- Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.Therapeutic advances in medical oncology · 2025Review
- From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps.Cancers · 2024Article
- Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer.Cancers · 2024Article
- Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT).Journal of gynecologic oncology · 2024Review
- Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.Journal of ovarian research · 2024Article
- Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.International journal of molecular sciences · 2024Review
- Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer.Materia socio-medica · 2024Article
- Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.Current cancer drug targets · 2024Article
- Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.Journal of gynecologic oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi.
methodsThe KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023.
trial registrationClinicalTrials.gov Identifier: NCT04734665.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.